Welcome to our dedicated page for Stereotaxis Ord news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis Ord stock.
Stereotaxis, Inc. develops robotic technologies for minimally invasive endovascular intervention, with recurring news centered on electrophysiology and arrhythmia treatment. Company updates cover the MAGiC™ Magnetic Interventional Ablation Catheter, MAGiC Sweep high density mapping catheter, Genesis and GenesisX robotic magnetic navigation systems, and related clinical use in complex heart-rhythm procedures.
News also includes FDA and international regulatory clearances or approvals, hospital robotic heart-arrhythmia program launches, commercialization of cath-lab technologies such as Synchrony™ and SynX™, manufacturing and product-pipeline progress, material agreements, capital-structure updates, and periodic operating and financial results.
Stereotaxis (NYSE: STXS) reported 2026 second quarter revenue of $7.7 million, down from $8.8 million a year earlier, with systems revenue at $1.5 million and recurring revenue at $6.2 million. Robotic catheter revenue surpassed $1 million, growing 270% sequentially, supported by initial Synchrony digital operating room sales following FDA clearance in April.
Gross margin was 58%, including 66% on recurring revenue and 29% on systems. Operating expenses were $9.1 million, including $2.5 million of non-cash charges, resulting in a net loss of $4.5 million. Negative free cash flow was $3.7 million. At June 30, 2026, the company held $10.5 million in cash and had no debt. Stereotaxis completed its previously announced acquisition of Robocath and reported the first U.S. purchase of a GenesisX robotic system, expected to be installed this fall.
Mobia Medical (Nasdaq: MOBI) appointed Myriam Curet, M.D. to its Board of Directors as an independent director, effective July 30, 2026. The company highlights her combination of clinical, executive and public company board experience to support its stroke recovery business.
Dr. Curet is a Clinical Professor of Surgery at Stanford University School of Medicine, holds a part-time clinical role at the Palo Alto VA Medical Center, and has previously held senior surgical posts at Stanford and the University of New Mexico. She also serves on the boards of Inspire Medical Systems (NYSE: INSP) and Stereotaxis (NYSE American: STXS) and is a Fellow of the American College of Surgeons.
Stereotaxis (NYSE: STXS) will release its second quarter 2026 financial results on Tuesday, August 11, 2026, after the U.S. market close. Management will host a conference call and webcast at 4:30 p.m. ET to discuss results and corporate developments, with live and replay access via phone and the investor relations section of the company’s website.
Stereotaxis (NYSE: STXS) announced that the University of Szeged has launched Hungary’s first advanced robotic cardiology program using the Genesis Robotic Magnetic Navigation System at its Cardiology Center. The hospital is the first in the country to establish a heart rhythm program based on this technology and has already successfully treated its first patients across a broad range of cardiac arrhythmias.
According to Stereotaxis and University leadership, Genesis is intended to improve the precision and safety of catheter ablation therapy, with expectations to treat hundreds of arrhythmia patients annually, serve as a central training institute, and support pioneering research in robotic cardiology.
Stereotaxis (NYSE: STXS) completed its acquisition of Robocath, integrating complementary robotic technologies for electrophysiology, interventional cardiology, and neurointerventions.
The deal combines platforms in endovascular robotics, with Stereotaxis noting expanded addressable markets and commercial synergies. Robocath’s CE- and NMPA-certified R-One system has shown over 98% technical success with no major adverse cardiovascular events.
Stereotaxis (NYSE: STXS) reported Q1 2026 revenue of $6.3 million, down from $7.5 million a year earlier, with a 60% gross margin and net loss of $5.9 million.
The company received U.S. FDA approval for its MAGiC catheter in January and FDA clearance for its Synchrony digital OR system in April, and signed a definitive agreement to acquire Robocath. Cash stood at $14.6 million with no debt. Stereotaxis guides to double-digit 2026 revenue growth, expecting revenue above $40 million and more than $10 million in both Q3 and Q4.
Stereotaxis (NYSE: STXS) announced the first United States patients treated with MAGiC™, its robotically-navigated magnetic ablation catheter, following FDA PMA approval on April 22, 2026. The initial U.S. case, performed by Dr. Nathan McConkey, treated complex congenital heart disease via basilic vein access with no recurrence in the weeks after the procedure. MAGiC is indicated for mapping, pacing, and creating endocardial lesions to treat supraventricular tachycardias in congenital heart disease patients with limited conventional access.
The release highlights improved catheter stability, contact force, and energy delivery and positions MAGiC to expand minimally invasive ablation options for challenging anatomy.
Stereotaxis (NYSE: STXS) will report its first quarter 2026 financial results after U.S. market close on Tuesday, May 12, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET to discuss results and corporate developments.
Dial-in numbers and a live/replay webcast will be available via the company’s investor relations website; a phone replay will be accessible for one month beginning about four hours after the call.
Stereotaxis (NYSE: STXS) announced a definitive agreement to acquire Robocath on April 15, 2026, combining magnetic navigation and mechanical robotics to target electrophysiology, interventional cardiology and neurointerventions.
The deal includes an upfront payment of $20 million, contingent payments up to $25 million, expected mid-2026 close, and estimated $2 million first-year revenue with breakeven by year three.
Stereotaxis (NYSE: STXS) announced FDA 510(k) clearance and commercial launch of the Synchrony system on April 6, 2026. Synchrony is a 55" 4K interventional lab display with ultra-low latency video, obsolescence protection, and cloud-based SynX for HIPAA/GDPR-compliant remote collaboration.
The company reiterated guidance of over $3 million in 2026 revenue from Synchrony placements independent of robotic systems and emphasized future AI-enabled applications and broader cath lab adoption.